by Margarida Maia, PhD | Nov 13, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend survival for people with malignant gliomas, the developer announced. Gliomas are a group of tumors that form...
by Marisa Wexler, MS | Nov 12, 2025 | Myeloma News
A combination of chemotherapy and immune-modulating therapies administered directly into the abdomen may help control ovarian cancer that has spread within the abdominal cavity, data from a small clinical trial show. Results from the study were discussed earlier this...
by Margarida Maia, PhD | Nov 12, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase) for adults with high-risk smoldering multiple myeloma, making it the first and only approved treatment for this slow-growing type of multiple myeloma. People with...
by Steve Bryson, PhD | Nov 10, 2025 | Myeloma News
One-time treatment with vispa-cel (CB-010), Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, resulted in durable responses in people with hard-to-treat large B-cell lymphoma (LBCL). That’s according to data from the ongoing Phase 1 ANTLER clinical...
by MM360 Staff | Nov 10, 2025 | Publications
J Natl Cancer Inst. 2025 Nov 9:djaf326. doi: 10.1093/jnci/djaf326. Online ahead of print. ABSTRACT INTRODUCTION: Although myeloma represents a key success story in oncology, some drugs have failed to meet primary endpoints in randomized controlled trials (RCTs),...
